Not only positive results of CXCR3 antagonists in vitro and in vivo in the preclinical model of BC have been obtained, but also positive results of various immune checkpoint inhibitors (ICIs) regulating CXCL9, CXCL10, and CXCL11 in clinical studies have been obtained (Karin, 2018). This evidence concerns the gene CXCL9 and breast cancer.